FDA studying physical attributes of generic drugs; Drug-device partnership to treat brain cancer debuts;

> The FDA is studying how the color, shape or size of a generic drug affects patient adherence, as it seeks to improve patient compliance with labeling and doctors' orders. More

> DNAtrix will use its Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, its candidate for treating a form of aggressive brain cancer known as glioblastoma. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.